Main Article Content
the drug with microcrystalline cellulose and other ingredients.The fabricated Mesalamine tablets were coated with Eudragit L100 polymer and HPMC E 15 LV. The fluctuation in colonic pH conditions during inflammatory bowel disease and the nature of less fluid content in the colon may limit the expected drug release in the colon. Addition of HPMC E 15 LV may control this problem by hydrophilic nature and excellent film-forming characteristics like ductility and elasticity.
The different batches of Mesalamine tablets (FM1-FM5) were coated with increasing concentration of Eudragit L100 and HPMC E 15 LV. The coating was given up to 8% TWG(Total weight gain) of the uncoated tablet. Drug release studies were conducted in different pH conditions in the presence of rat ceaecal contents. The different buffer conditions were chosen to mimic the pH changes in the terminal part of the ileum as well as in the colon. The drug release profile was analyzed for colon-targeting performance in vitro. The release profile of the tablets indicates that the drug release was retarded in the tablet by film coating. The addition of HPMC E 15 LV ensures the channels for allowing colonic fluids to penetrate into the core and subsequent drug release at the target site. The kinetics of the drug release also evaluated the release pattern that was best fitted with Higuchian release. The results of the mechanism of release revealed that drug release was found to be a complex one with diffusion, erosion and swelling.
This is an Open Access article distributed under the terms of the Attribution-Noncommercial 4.0 International License [CC BY-NC 4.0], which requires that reusers give credit to the creator. It allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, for noncommercial purposes only.
James S Chu. Advances in colon-specific drug delivery system employingthe CODES TM. The drug delivery companies report autumn/winter Â©Pharma ventures Ltd 2003:39-40.
Drossman DA, Li Z, Andruzzi E, Temple RD, Talley NJ, Thompson WG,et al. U. S householder survey of functional gastrointestinal disorder.
prevalence, sociodemography, and health impact. Dig Dis Sci
Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002;347:417- 29.
Khan MZ, Prebeg Z, KurjakoviÄ‡ N. A pH-dependent colon targeted oral drug delivery system using methacrylic acid copolymers I. Manipulation Of drug release using Eudragit L100-55 and Eudragit S100 combinations.J Control Release 1999;58:215-22.
Yang L, Chu J, Fix JA. Colon-specific drug delivery: New approaches and in vitro/in vivo evaluation. Int J Pharm 2002;235:1-15.
Ardizzone S, Bianchi Porro G. A practical guide to management of distal ulcerative colitis. Drugs 1998;55:519-42.
Singh BN. Modified-release solid formulations for colonic delivery.
Recent Pat Drug Deliv Formul 2007;1:53-63.
Singh BN, Kim KH, Swarbrick J, Boylan JC. Encylopedia of Phrmaceutical
Technology, New York: Marcel Dekker, Inc; 2002. p. 886-909.
Follonier N, Cole ET. Evolution of hot melt extrusion as a new technique for the production of polymer based pellets for sustained release
capsule containing high loadings freely soluble drugs. Drug Dev Ind
Saffarin M, Kumar GS, Savariar C, BurnhamJC, Williams F,
Neckers DC. A New approach to the oral administration of insulin and
other peptide drugs. Science 1986;233:1081-4.
Ashford M, Fell JT. Targeting drugs to the colon: Delivery systems for
oral administration. J Drug Target 1994;2:241-57.
Wakerly Z, Fell JT, Attwood D. Parkins. Studies on drug release from
pectin/ethylcellulose film-coated tablets: A potential colonic delivery
systems. Int J Pharm 1997;153:219-24.
Evans DF, Pye G, Bramley R, Clark AG, Dyson TJ, Hardcastle JD. Measurement of gastrointestinal pH profiles in normal ambulant human subjects. Gut 1988;29:1035-41.
Ashford, M, Fell, JT, Attwood D, Sharma H. Woodhead P. An in vitro
investigation into the suitability of pH- dependent polymers for colon
targeting. Int J Pharm 1993;91:241-5.
Nugent SG, Kumar D, Rampton DS, Evans DF. Intestinal luminal pH in inflammatory bowel disease: Possible determination and implications
for therapy with aminosalicylates and other drugs. Gut 2001;48:571-7.
Takaya T, Niwa K, Muraka M, Ogita I, Nagai N, Yano R, et al. Importance of dissolution process on systemic availability of drugs delivered by colon delivery system. J Control Release 1998;50:111-22.
Basit A, Bloor J. Perspective on colonic drug delivery. Business briefing. Pharma tech 2003:185-90.
Khan MZ. Dissolution testing for sustained or controlled release
Oral dosage forms and correlation with in vivo data: Challenges and
opportunities. Int J Pharm 1996;140:131-4.
Dressman JB, Amidon GL, Reppas C, Shah VP. Dissolution testing as aprognostic tool for oral drug absorption: Immediate release dosage
forms. Pharm Res 1998;15:11-22.
Ramusen SN, Binder V, Maier K, Bondesen S, Fischer C, Klotz U, et al.Treatment of Crohnâ€™s disease with peroral 5-amiino salicylic acid.
Stolk LM, Rietbroek R, Wiltink EH, Tukker JJ. Dissolution profile of
mesalazine formuations in vitro. Pharm Weekbl Sci 1990:200-4.
Fallingborg J, Christensen LA, Jacobsen BA, Ramusen SN. Very low
intraluminal colonic pH in patients with active ulcerative colitis. Dig.
Dis Sci 1993;38:1989-93.
Ofori-Kwakye K, Fell JT. Biphasic drug release: The permeability of film containing pectin, chitosan and HPMC. Int J Pharm 2001;226:139-45.
Yuen KH, Deshmukh AA, Newton JM. Development and in-vitro
evaluation of a multiparticulate sustained release theophylline
formulation. Drug Dev Ind Pharm 1993;19:855-74.
Frohoffâ€“Hulsmann MA, Schmitz A, Lippold BC. Aqueous ethyl cellulose dispersion containing plasticizers of different water solubility and
hydroxylpropyl methyl-cellulose as coating material for diffusion
pellets. I. Drug release rates from coated pellets. IntJ Pharm 1999;177:69-82.
Chan LW, Ong KT, Heng PW, Novel film modifiers to alter the physical
properties of composite ethylcellulose films. Pharm Res 2005;22:476- 89.